Search

Your search keyword '"Jörg Trojan"' showing total 2 results
Start Over Author "Jörg Trojan" Publisher mdpi ag
2 results on '"Jörg Trojan"'

1. Low Platelet Count Predicts Reduced Survival in Potentially Resectable Hepatocellular Carcinoma

Author

Christopher Schrecker, Oliver Waidmann, Hanan El Youzouri, Jörg Trojan, Andreas Anton Schnitzbauer, Wolf Otto Bechstein, Stefan Zeuzem, and Christine Koch

Subjects
hepatocellular carcinoma, platelet count, thrombocytopenia, thrombocytosis, cirrhosis, portal hypertension, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

The prognostic role of platelet count in hepatocellular carcinoma (HCC) remains unclear, and in fact both thrombocytopenia and thrombocytosis are reported as predictors of unfavourable outcomes. This study aimed to clarify the prognostic value of preoperative platelet count in potentially resectable HCC. We retrospectively reviewed 128 patients who underwent hepatic resection for HCC at a tertiary academic centre (2007–2019). Patient data were modelled by regression analysis, and platelet count was treated as a continuous variable. 89 patients had BCLC 0/A tumours and 39 had BCLC B tumours. Platelet count was higher in patients with larger tumours and lower in patients with higher MELD scores, advanced fibrosis, and portal hypertension (p < 0.001 for all listed variables). After adjusting for BCLC stage and tumour diameter, low platelet count associated with reduced overall survival (hazard ratio 1.25 per 50/nL decrease in platelet count, 95% confidence interval (CI) 1.02–1.53, p = 0.034) and increased perioperative mortality (odds ratio 1.96 per 50/nL decrease in platelet count, 95% CI 1.19–3.53, p = 0.014). Overall, low platelet count correlates with increased liver disease severity, inferior survival, and excess perioperative mortality in resectable HCC. These insights might be applied in clinical practice to better select patients for resection.

Published
2022
Full Text
View/download PDF

2. Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer

Author

Gabriele D. Maurer, Benedikt Sauer, Jörg Trojan, Joachim P. Steinbach, Anna-Luisa Luger, Nadja I Lorenz, Patrick N. Harter, Hans Urban, Michael W. Ronellenfitsch, Michel Mittelbronn, and C. Stroh

Subjects
0301 basic medicine, Cancer Research, Bevacizumab, Colorectal cancer, colon carcinoma, medicine.disease_cause, lcsh:RC254-282, Article, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Medicine, Epidermal growth factor receptor, neoplasms, Tumor microenvironment, biology, Cetuximab, business.industry, hypoxia, cetuximab-bevacizumab therapy sequence, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, digestive system diseases, Vascular endothelial growth factor, 030104 developmental biology, Oncology, chemistry, 030220 oncology & carcinogenesis, Cancer research, biology.protein, KRAS, Erlotinib, business, epidermal growth factor receptor, medicine.drug, vascular endothelial growth factor receptor
Abstract

Monoclonal antibodies like cetuximab, targeting the epidermal growth factor receptor (EGFR), and bevacizumab, targeting the vascular endothelial growth factor (VEGF), are an integral part of treatment regimens for metastasized colorectal cancer. However, inhibition of the EGFR has been shown to protect human glioma cells from cell death under hypoxic conditions. In colon carcinoma cells, the consequences of EGFR blockade in hypoxia (e.g., induced by bevacizumab) have not been evaluated yet. LIM1215 and SW948 colon carcinoma and LNT-229 glioblastoma cells were treated with cetuximab, PD153035, and erlotinib and analyzed for cell density and viability. The sequential administration of either cetuximab followed by bevacizumab (CET-&gt, BEV) or bevacizumab followed by cetuximab (BEV-&gt, CET) was investigated in a LIM1215 (KRAS wildtype) and SW948 (KRAS mutant) xenograft mouse model. In vitro, cetuximab protected from hypoxia. In the LIM1215 model, a survival benefit with cetuximab and bevacizumab monotherapy was observed, but only the sequence CET-&gt, BEV showed an additional benefit. This effect was confirmed in the SW948 model. Our observations support the hypothesis that bevacizumab modulates the tumor microenvironment (e.g., by inducing hypoxia) where cetuximab could trigger protective effects when administered later on. The sequence CET-&gt, BEV therefore seems to be superior as possible mutual adverse effects are bypassed.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results